Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID05499637

Pilot Study to Evaluate the Accuracy of [68Ga]Ga-PentixaFor PET/CT in Diagnosing Three Types of Acute Myocardial Inflammation

Led by John O. Prior · Updated on 2026-05-11

69

Participants Needed

1

Research Sites

4 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are investigating acute myocardial inflammation, a complex condition that includes acute cellular cardiac allograft rejection (ACR), cardiac sarcoidosis (CS), and immune checkpoint inhibitor induced myocarditis (ICIM). This study aims to evaluate the accuracy of [68Ga]Ga-PentixaFor PET/CT imaging for detecting inflammatory cells in these patients, offering a potentially non-invasive diagnostic option. The study is a phase 2 trial focusing on these specific heart inflammation conditions where diagnosis is currently challenging. Participants will receive an intravenous injection of a maximum of 50 micrograms of PentixaFor labeled with 150 ±15 MBq of Gallium-68 ([68Ga]) as a bolus 60 ±15 minutes before undergoing PET/CT imaging. The treatment involves this imaging procedure for all three patient groups (ACR, CS, ICIM) to assess the presence and characteristics of myocardial inflammation. During the study, researchers will evaluate imaging results by analyzing lesion number, location, and standardized uptake value (SUV) over one year. They will also monitor toxicity data for safety assessment. Participants will have regular clinical follow-ups at the cardiology department. The study involves signing informed consent and includes monitoring for any adverse effects related to the imaging agent or procedures throughout the study duration.

CONDITIONS

Brief Title

[68Ga]Ga-PentixaFor PET/CT in Acute Myocardial Inflammation

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Signed written informed consent
  • Male or female
  • Age 18 years or older
  • Patients suspected of cardiac sarcoidosis or immune checkpoint inhibitor induced myocarditis, or in first year after heart transplantation
  • Receiving standard clinical follow-up at the cardiology department
Not Eligible

You will not qualify if you...

  • No signed written informed consent
  • Age under 18 years
  • Claustrophobia
  • Myocardial ischemia detected by non-invasive perfusion test or coronary angiography in cardiac sarcoidosis or immune checkpoint inhibitor induced myocarditis groups
  • Clinically unstable cardiovascular conditions including unstable brady-tachyarrhythmia, severe hypo- or hypertension with systolic blood pressure below 90 mmHg or above 220 mmHg, or cardiogenic shock
  • Pregnant or breastfeeding women
  • Planning pregnancy during the study in cardiac sarcoidosis group
  • Previous enrollment in this study
  • Moderate to severe renal insufficiency with contraindication to gadolinium in cardiac sarcoidosis or immune checkpoint inhibitor induced myocarditis groups
  • Investigator, family members, employees, or dependent persons enrolled
  • Any disease or condition interfering with study objectives as judged by investigator
  • Insufficient knowledge of project language or inability to consent or follow procedures
  • Refusal to be informed about incidental findings by exercising "right not to know"

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Diagnostic Evaluation

Duration - Single day procedure

Participants receive an injection of [68Ga]Ga-PentixaFor followed by PET/CT imaging to diagnose acute myocardial inflammation.

1 visit (in-person)

Long-term Monitoring

Duration - 1 year

Participants are monitored for imaging results and toxicity over the following year.

Follow-up visits as needed during 1 year

Trial Site Locations

Total: 1 location

1

Centre Hospitalier Universitaire Vaudois

Lausanne, Canton of Vaud, Switzerland, 1011

Actively Recruiting

Loading map...

Research Team

J

John O Prior, MD, PhD

C

Christel Kamani, MD

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NON_RANDOMIZED

Model

PARALLEL

Primary Purpose

DIAGNOSTIC

Number of Arms

3

Similar Trials

Cardiac Sarcoidosis Multi-Center Randomized Controlled Trial...

Cardiac Sarcoidosis

Actively Recruiting

30 locations

Cardiomyopathies and Heart Muscle Diseases: Cardiac Imaging ...

Heart Failure With Preserved Ejection Fraction

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here